JP2004503232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004503232A5 JP2004503232A5 JP2002510501A JP2002510501A JP2004503232A5 JP 2004503232 A5 JP2004503232 A5 JP 2004503232A5 JP 2002510501 A JP2002510501 A JP 2002510501A JP 2002510501 A JP2002510501 A JP 2002510501A JP 2004503232 A5 JP2004503232 A5 JP 2004503232A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense compound
- antisense
- ebpβ
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000692 anti-sense effect Effects 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 239000000074 antisense oligonucleotide Substances 0.000 claims 7
- 238000012230 antisense oligonucleotides Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000001246 colloidal dispersion Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/593,711 US6271030B1 (en) | 2000-06-14 | 2000-06-14 | Antisense inhibition of C/EBP beta expression |
| PCT/US2001/018763 WO2001096360A1 (en) | 2000-06-14 | 2001-06-11 | Antisense modulation of c/ebp beta expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004503232A JP2004503232A (ja) | 2004-02-05 |
| JP2004503232A5 true JP2004503232A5 (enExample) | 2005-02-03 |
Family
ID=24375831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002510501A Withdrawn JP2004503232A (ja) | 2000-06-14 | 2001-06-11 | Ｃ／ＥＢＰβ発現のアンチセンスモジュレーション |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6271030B1 (enExample) |
| EP (1) | EP1294737A1 (enExample) |
| JP (1) | JP2004503232A (enExample) |
| AU (1) | AU2001268307A1 (enExample) |
| WO (1) | WO2001096360A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040121973A1 (en) * | 2002-02-05 | 2004-06-24 | Monia Brett P | Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression |
| US20030166592A1 (en) * | 1999-07-19 | 2003-09-04 | Monia Brett P. | Antisense modulation of liver glycogen phosphorylase expression |
| US6271030B1 (en) * | 2000-06-14 | 2001-08-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of C/EBP beta expression |
| AU8448301A (en) * | 2000-09-08 | 2002-03-22 | Suntory Ltd | Remedies for heart failure |
| US20030083304A1 (en) * | 2001-10-09 | 2003-05-01 | Smart Robert C. | CCAAT/enhancer binding protein-beta (C/EBPbeta) is a molecular target for cancer treatment |
| CA2425021A1 (en) * | 2002-04-12 | 2003-10-12 | Sumitomo Electric Industries, Ltd. | Control of the ratio of lap to lip |
| US20030232773A1 (en) * | 2002-06-17 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of DRAK1 expression |
| US20040077084A1 (en) * | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
| EP1606305A4 (en) * | 2003-03-12 | 2009-06-24 | Vasgene Therapeutics Inc | NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH |
| EP1799867A2 (en) * | 2004-09-23 | 2007-06-27 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
| IL177989A0 (en) * | 2006-09-10 | 2006-12-31 | Yeda Res & Dev | Use of transcription factor inhibitor in the manufacture of a medicament |
| MX2022001769A (es) * | 2019-08-14 | 2022-06-09 | Codiak Biosciences Inc | Construcciones de vesícula extracelular-oligonucleótido antisentido (aso) que se dirigen a la proteína beta de unión al potenciador ccaat (cebp)/beta. |
| GB202019692D0 (en) * | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2686565B2 (ja) | 1989-12-25 | 1997-12-08 | 忠三 岸本 | Ｃ／ｅｂｐ２遺伝子及びリコンビナントｃ／ｅｂｐ２ |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6271030B1 (en) * | 2000-06-14 | 2001-08-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of C/EBP beta expression |
-
2000
- 2000-06-14 US US09/593,711 patent/US6271030B1/en not_active Expired - Lifetime
-
2001
- 2001-06-11 WO PCT/US2001/018763 patent/WO2001096360A1/en not_active Ceased
- 2001-06-11 JP JP2002510501A patent/JP2004503232A/ja not_active Withdrawn
- 2001-06-11 US US10/297,056 patent/US20060030045A1/en not_active Abandoned
- 2001-06-11 EP EP01946229A patent/EP1294737A1/en not_active Withdrawn
- 2001-06-11 AU AU2001268307A patent/AU2001268307A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004513626A5 (enExample) | ||
| JP2004509619A5 (enExample) | ||
| CA2397590A1 (en) | Antisense inhibition of ptp1b expression | |
| JP2003523739A5 (enExample) | ||
| JP2005520489A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2018150344A5 (enExample) | ||
| JP2009508527A5 (enExample) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP2005503142A5 (enExample) | ||
| JP2007505627A5 (enExample) | ||
| JP2004503232A5 (enExample) | ||
| CA2451643A1 (en) | Antisense modulation of superoxide dismutase 1, soluble expression | |
| JP2004535179A5 (enExample) | ||
| JP2018184423A5 (enExample) | ||
| US20220170020A1 (en) | Antisense oligonucleic acid | |
| BR112021014940A2 (pt) | Oligonucleotídeo, composição de oligonucleotídeo quiralmente controlada, composição farmacêutica, e método de tratamento, prevenção, atraso de início e/ou diminuição da gravidade de pelo menos um sintoma de doença de huntington | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2010505432A5 (enExample) | ||
| JP2021527437A (ja) | Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド | |
| CN101980726A (zh) | 治疗与dna重复不稳定性相关的遗传病症的方法和装置 | |
| JP2010539950A5 (enExample) | ||
| CN106459972A (zh) | 用于调节sod‑1表达的组合物 | |
| JP2008523157A5 (enExample) | ||
| CA2343102A1 (en) | Antisense modulation of survivin expression |